Plasmidsaurus

Plasmidsaurus

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Plasmidsaurus is a disruptive, asset-light sequencing-as-a-service company that has rapidly gained traction by offering exceptionally fast turnaround times and publication-grade accuracy. By leveraging partnerships with leading technology providers like Oxford Nanopore and operating a decentralized network of labs and dropboxes, it provides accessible, hassle-free sequencing to over 70,000 scientists. The company has positioned itself as a critical enabler for R&D across genetics, synthetic biology, and therapeutic development, with a strong focus on customer experience and technical innovation.

Genetics & GenomicsSynthetic Biology

Technology Platform

Technology-agnostic sequencing-as-a-service platform leveraging partnerships with leading hardware providers (e.g., Oxford Nanopore) for early access to latest chemistries, combined with a proprietary bioinformatics pipeline and a global network of labs and dropboxes for ultrafast sample processing and data delivery.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The company is positioned to capitalize on the growing trend of outsourcing sequencing in life sciences, especially in fast-moving fields like gene therapy (AAV sequencing) and synthetic biology.
Its global dropbox network and ultrafast model are key differentiators to capture market share from slower, traditional service providers.

Risk Factors

Key risks include dependence on sequencing technology partners for supply and innovation, intense competition in the sequencing services market on price and convenience, and operational risks in maintaining ultrafast turnaround times across a decentralized global lab network.

Competitive Landscape

Plasmidsaurus competes in the fragmented DNA sequencing services market against large commercial providers (e.g., Azenta/GENEWIZ, QuintaraBio), academic core facilities, and in-house capabilities at pharma companies. Its primary competitive advantages are its exceptional speed, strong focus on user experience, and specialized applications like whole plasmid and AAV sequencing.